Sorafenib
Information
- Drug Name
- Sorafenib
- Description
- Entry(CIViC)
- 33
CIViC
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| In an in-vitro study using an in vitro saturation ... | FLT3 |
FLT3 p.Asp835Tyr (p.D835Y) ( ENST00000241453.12 ) FLT3 p.Asp835Tyr (p.D835Y) ( ENST00000241453.12 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| 13 patients with relapsed or chemo-refractory FLT3... | FLT3 |
FLT3 p.Asp835Tyr (p.D835Y) ( ENST00000241453.12 ) FLT3 p.Asp835Tyr (p.D835Y) ( ENST00000241453.12 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| 13 patients with relapsed or chemo-refractory FLT3... | FLT3 | FLT3 ITD FLT3 ITD | Sensitivity | true | CIViC Evidence | detail |
| COS-7 cells were transiently transfected with expr... | KDR |
KDR p.Ala1065Thr (p.A1065T) ( ENST00000263923.5 ) KDR p.Ala1065Thr (p.A1065T) ( ENST00000263923.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| COS-7 cells were transiently transfected with expr... | KDR |
KDR p.Asp717Val (p.D717V) ( ENST00000263923.5 ) KDR p.Asp717Val (p.D717V) ( ENST00000263923.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| In a phase 2 clinical trial of sorafenib in patien... | RET |
RET p.Met918Thr (p.M918T) ( ENST00000340058.6, ENST00000713926.1, ENST00000355710.8, ENST00000615310.5 ) RET p.Met918Thr (p.M918T) ( ENST00000340058.6, ENST00000355710.8, ENST00000615310.5, ENST00000713926.1 ) |
Sensitivity | true | CIViC Evidence | detail |
| Preclinical study in melanoma cell lines. Inactivi... | BRAF |
BRAF p.Asp634Ala (p.D634A) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Asp634Ala (p.D634A) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
Sensitivity | true | CIViC Evidence | detail |
| Preclinical study in melanoma cell lines. Inactivi... | BRAF |
BRAF p.Asp634Val (p.D634V) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Asp634Val (p.D634V) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
Sensitivity | true | CIViC Evidence | detail |
| Preclinical study in melanoma cell lines. Inactivi... | BRAF |
BRAF p.Lys523Met (p.K523M) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Lys523Met (p.K523M) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
Sensitivity | true | CIViC Evidence | detail |
| Retrospective analysis of somatic mutations and co... | CCND1 |
CCND1 AMPLIFICATION ( ENST00000227507.3 ) CCND1 AMPLIFICATION ( ENST00000227507.3 ) |
Sensitivity | true | CIViC Evidence | detail |
| Retrospective analysis of somatic mutations and co... | RAF1 |
RAF1 AMPLIFICATION ( ENST00000251849.9 ) RAF1 AMPLIFICATION ( ENST00000251849.9 ) |
Sensitivity | true | CIViC Evidence | detail |
| Retrospective analysis of somatic mutations and co... | KRAS |
KRAS AMPLIFICATION ( ENST00000256078.10 ) KRAS AMPLIFICATION ( ENST00000256078.10 ) |
Sensitivity | true | CIViC Evidence | detail |
| Six children with relapsed or refractory FLT3-ITD-... | FLT3 | FLT3 ITD FLT3 ITD | Sensitivity | true | CIViC Evidence | detail |
| Three children with relapsed or refractory FLT3-IT... | FLT3 |
FLT3 p.Asp835His (p.D835H) ( ENST00000241453.12 ) FLT3 p.Asp835His (p.D835H) ( ENST00000241453.12 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| Mouse Ba/F3 cells with FLT3 mutations were evaluat... | FLT3 |
FLT3 p.Asp835His (p.D835H) ( ENST00000241453.12 ) FLT3 p.Asp835His (p.D835H) ( ENST00000241453.12 ) FLT3 p.Asp835Tyr (p.D835Y) ( ENST00000241453.12 ) FLT3 p.Asp835Tyr (p.D835Y) ( ENST00000241453.12 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| Phase 2 study in Asian patients with unresectable ... | KRAS | KRAS MUTATION KRAS MUTATION | Sensitivity | true | CIViC Evidence | detail |
| A patient with a malignant spindle cell tumor of t... | BRAF | BRAF KIAA1549-BRAF | Sensitivity | true | CIViC Evidence | detail |
| In one patient with S214C mutation, the use of sor... | ARAF |
ARAF p.Ser214Cys (p.S214C) ( ENST00000377045.9 ) ARAF p.Ser214Cys (p.S214C) ( ENST00000377045.9 ) |
Sensitivity | true | CIViC Evidence | detail |
| Emergence of D835 mutation in AML patients with FL... | FLT3 |
FLT3 p.Asp835Tyr (p.D835Y) ( ENST00000241453.12 ) FLT3 p.Asp835Tyr (p.D835Y) ( ENST00000241453.12 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| Sorafenib is effective in patients with FLT3 inter... | FLT3 |
FLT3 p.Asp835Tyr (p.D835Y) ( ENST00000241453.12 ) FLT3 p.Asp835Tyr (p.D835Y) ( ENST00000241453.12 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| Sorafenib is effective in patients with FLT3 inter... | FLT3 | FLT3 ITD FLT3 ITD | Sensitivity | true | CIViC Evidence | detail |
| The melanoma cell line WM3211, which harbors the L... | KIT |
KIT p.Leu577Pro (p.L577P) ( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Leu577Pro (p.L577P) ( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| Sorafenib can inhibit ARF-mediated MEK phosphoryla... | ARAF |
ARAF p.Ser214Cys (p.S214C) ( ENST00000377045.9 ) ARAF p.Ser214Cys (p.S214C) ( ENST00000377045.9 ) |
Sensitivity | true | CIViC Evidence | detail |
| In this preclinical study, melanoma cell lines har... | BRAF |
BRAF p.Asp634Gly (p.D634G) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Asp634Gly (p.D634G) ( ENST00000646891.2, ENST00000496384.7, ENST00000644969.2, ENST00000288602.11 ) |
Sensitivity | true | CIViC Evidence | detail |
| In this preclinical study, melanoma cell lines har... | BRAF |
BRAF p.Gly509Glu (p.G509E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Gly509Glu (p.G509E) ( ENST00000496384.7, ENST00000288602.11, ENST00000644969.2, ENST00000646891.2 ) |
Sensitivity | true | CIViC Evidence | detail |
| BRAF fusion AGK-BRAF was associated with decreased... | BRAF | BRAF AGK-BRAF | Sensitivity | true | CIViC Evidence | detail |
| In a preclinical trial, the AML cell line Kasumi-1... | KIT |
KIT p.Asn823Lys (p.N823K) ( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687246.1, ENST00000687109.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Asn823Lys (p.N823K) ( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) |
Sensitivity | false | CIViC Evidence | detail |
| In a preclinical trial, the AML cell line KG1 with... | FGFR1 | FGFR1 FGFR1 FUSIONS FGFR1 FGFR1 FUSIONS | Sensitivity | false | CIViC Evidence | detail |
| In a preclinical trial, the AML cell line EOL1with... | PDGFRA | PDGFRA FIP1L1-PDGFRA | Sensitivity | true | CIViC Evidence | detail |
| In a preclinical trial, the leukemic cell line MV4... | FLT3 | FLT3 ITD FLT3 ITD | Sensitivity | true | CIViC Evidence | detail |
| In 66 patients with advanced renal cell carcinoma,... | HMOX1 | HMOX1 EXPRESSION HMOX1 EXPRESSION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| Cetuximab or panitumumab may be ineffective in pat... | BRAF |
BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
Sensitivity | true | CIViC Evidence | detail |
| CD133 (PROM1) expression in 39 samples of hepatoce... | PROM1 | PROM1 EXPRESSION PROM1 EXPRESSION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| Mucosal melanoma; no active control trial (histori... | KIT | KIT UNKNOWN | Sensitivity | true | MMMP | detail |
| Melanoma cells expressing no ectopic C-Raf were mo... | RAF1 | RAF1 EXPRESSION | Sensitivity | true | MMMP | detail |
| In vitro testing showed that the cell viability of... | KIT | KIT L576P | Resitance or Non-Reponse | true | MMMP | detail |
| Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor. ... | RAF1 | RAF1 EXPRESSION | Sensitivity | true | MMMP | detail |
| Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor | AKT1 | AKT1 UNDEREXPRESSION | Sensitivity | true | MMMP | detail |
| Despite stabilizing IFNAR, Sorafenib - while inhib... | IFNAR1 | IFNAR1 OVEREXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
| Soluble Tie2 inhibits the Tie2 pathway (Tie2 is th... | TEK | TEK UNDEREXPRESSION | Sensitivity | true | MMMP | detail |
| Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor | GSK3B | GSK3B UNDEREXPRESSION | Sensitivity | true | MMMP | detail |
| Sorafenib (BRAF, CRAF, VEGFR and PDGFR inhibitor) ... | AIFM1 | AIFM1 UNDEREXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
| Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor. ... | BRAF | BRAF V600E | Sensitivity | true | MMMP | detail |
| Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor. ... | BRAF | BRAF V600E | Resitance or Non-Reponse | true | MMMP | detail |
| Tumor response was not associated with BRAF mutati... | BRAF | BRAF V600E | Resitance or Non-Reponse | true | MMMP | detail |
| Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor. ... | BRAF | BRAF V600E | Resitance or Non-Reponse | true | MMMP | detail |
| Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor | BRAF | BRAF V600E | Resitance or Non-Reponse | true | MMMP | detail |
| Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor | BRAF | BRAF D595G | Sensitivity | true | MMMP | detail |
| Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor | BRAF | BRAF G469E | Sensitivity | true | MMMP | detail |
| Sorafenib: BRAF, CRAF, VEGFR and PDGFR inhibitor | BRAF | BRAF V600E | Resitance or Non-Reponse | true | MMMP | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00494182 | Active, not recruiting | Phase 2 | Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer | April 25, 2007 | December 31, 2025 |
| NCT02143726 | Active, not recruiting | Phase 2 | Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer | October 1, 2014 | August 6, 2024 |
| NCT02143401 | Active, not recruiting | Phase 1 | Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors | November 7, 2014 | May 20, 2025 |
| NCT04723004 | Active, not recruiting | Phase 3 | Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC | October 15, 2020 | December 31, 2024 |
| NCT04710641 | Active, not recruiting | Phase 2 | Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone | January 1, 2022 | May 1, 2025 |
| NCT04039607 | Active, not recruiting | Phase 3 | A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma | September 30, 2019 | September 30, 2026 |
| NCT03298451 | Active, not recruiting | Phase 3 | Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma | October 11, 2017 | August 27, 2024 |
| NCT03247088 | Active, not recruiting | Phase 1/Phase 2 | Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant | July 30, 2017 | December 31, 2024 |
| NCT03164057 | Active, not recruiting | Phase 2 | A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia | June 15, 2017 | June 2027 |
| NCT03755791 | Active, not recruiting | Phase 3 | Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy | June 10, 2018 | December 1, 2024 |
| NCT04770896 | Active, not recruiting | Phase 3 | A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab | April 26, 2021 | July 9, 2025 |
| NCT01946529 | Active, not recruiting | Phase 2 | Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors | December 27, 2013 | July 2026 |
| NCT03533582 | Active, not recruiting | Phase 2/Phase 3 | Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery | May 24, 2018 | June 30, 2026 |
| NCT01871766 | Active, not recruiting | Phase 2 | Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy | December 4, 2013 | June 2030 |
| NCT04763408 | Active, not recruiting | A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma | April 9, 2021 | March 7, 2031 | |
| NCT03439891 | Active, not recruiting | Phase 2 | Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer | April 16, 2018 | November 30, 2024 |
| NCT05889949 | Active, not recruiting | Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma | June 1, 2019 | May 31, 2023 | |
| NCT01840592 | Active, not recruiting | Phase 2 | Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib | April 2013 | April 2025 |
| NCT01730937 | Active, not recruiting | Phase 3 | Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer | April 2013 | July 1, 2027 |
| NCT01658878 | Active, not recruiting | Phase 1/Phase 2 | An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer | October 30, 2012 | June 28, 2024 |
| NCT03017326 | Active, not recruiting | Phase 3 | Paediatric Hepatic International Tumour Trial | August 24, 2017 | August 1, 2027 |
| NCT02298348 | Active, not recruiting | Phase 1 | Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma | October 8, 2015 | December 2024 |
| NCT01187199 | Active, not recruiting | Phase 1 | Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer | August 19, 2010 | April 30, 2026 |
| NCT00493636 | Completed | Phase 2 | 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy | June 2007 | November 2012 |
| NCT00495872 | Completed | Phase 1 | Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor | June 2007 | |
| NCT00509613 | Completed | Phase 1 | Phase 1 Study With Sorafenib and Sirolimus | June 2007 | |
| NCT00510250 | Completed | Phase 1/Phase 2 | A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer | June 2007 | July 2015 |
| NCT00536575 | Completed | Phase 1/Phase 2 | Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients | November 2007 | August 2010 |
| NCT00542971 | Completed | Phase 1/Phase 2 | Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006) | October 2007 | May 2011 |
| NCT00543504 | Completed | Phase 1 | Bevacizumab in Multiple Phase I Combinations | October 10, 2007 | April 29, 2020 |
| NCT00544167 | Completed | N/A | Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer | May 2007 | April 2011 |
| NCT00544609 | Completed | Phase 1 | Sorafenib and Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent | December 2007 | May 2012 |
| NCT00544817 | Completed | Phase 2 | Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme | April 2007 | August 2010 |
| NCT00572078 | Completed | Phase 1 | Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors | January 23, 2008 | September 14, 2014 |
| NCT00602862 | Completed | N/A | Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250 | July 2007 | June 2012 |
| NCT00605566 | Completed | Phase 2 | Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors | January 2008 | February 2015 |
| NCT00606866 | Completed | Phase 3 | MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma | July 2004 | June 2008 |
| NCT00609804 | Completed | Phase 2 | Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib | March 2008 | November 2014 |
| NCT00609934 | Completed | Phase 1/Phase 2 | Study of Sorafenib and Palliative Radiotherapy in Kidney Cancer That Spreads to the Bone | December 2007 | October 2014 |
| NCT00610246 | Completed | Phase 1 | A Study of Radiation With Sorafenib in Advanced Cancer | May 2007 | May 2011 |
| NCT00623402 | Completed | Phase 2 | Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma | January 2008 | |
| NCT00634634 | Completed | Phase 1/Phase 2 | Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer | August 11, 2008 | April 28, 2023 |
| NCT00634751 | Completed | Phase 1/Phase 2 | CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma | February 2008 | July 2010 |
| NCT00635791 | Completed | Phase 1 | Phase I Study of Vorinostat and Sorafenib in Advanced Cancer | March 2008 | March 2012 |
| NCT00639262 | Completed | Phase 1 | Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors | March 2008 | September 2012 |
| NCT00654238 | Completed | Phase 2 | Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer | February 2006 | March 2011 |
| NCT00661830 | Completed | Phase 2 | Gemcitabine and Sorafenib in Advanced Biliary Tract Cancer (GEMSO) | May 2008 | June 2010 |
| NCT00665990 | Completed | Phase 1 | Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia | November 2007 | August 2013 |
| NCT00678392 | Completed | Phase 3 | Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer | September 3, 2008 | February 25, 2016 |
| NCT00696696 | Completed | Phase 2 | Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer | September 2007 | June 2013 |
| NCT00703638 | Completed | Phase 1 | Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors | May 2008 | November 2010 |
| NCT00712790 | Completed | Phase 1/Phase 2 | Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC) | June 2008 | April 2014 |
| NCT00712855 | Completed | Phase 1 | A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma | June 2008 | August 2012 |
| NCT00759928 | Completed | Phase 1 | PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors | October 2008 | June 2014 |
| NCT00768937 | Completed | Phase 1/Phase 2 | Sorafenib and Transarterial Chemoembolization for Hepatocellular Carcinoma | September 2008 | November 2010 |
| NCT00064350 | Completed | Phase 2 | Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer | June 28, 2004 | March 2011 |
| NCT00217620 | Completed | Phase 2 | S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas | March 2006 | September 2012 |
| NCT00373373 | Completed | Phase 2 | Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML | September 2006 | July 2009 |
| NCT00390611 | Completed | Phase 2 | Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer | October 2006 | April 2014 |
| NCT00392821 | Completed | Phase 1/Phase 2 | Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer | December 2006 | October 2013 |
| NCT00398814 | Completed | Phase 1 | Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers | October 2006 | October 2011 |
| NCT00411671 | Completed | Phase 2 | BATTLE Program: Sorafenib in Patients With NSCLC | November 2006 | November 2012 |
| NCT00414388 | Completed | Phase 1/Phase 2 | Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer | December 2006 | March 2012 |
| NCT00418496 | Completed | Phase 1 | Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma | November 8, 2006 | October 2013 |
| NCT00445042 | Completed | Phase 2 | Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer | November 2005 | October 2008 |
| NCT00448149 | Completed | Phase 1/Phase 2 | Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer | December 2006 | June 2009 |
| NCT00449280 | Completed | Phase 1 | Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies | November 2006 | September 2009 |
| NCT00452218 | Completed | Phase 1 | Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH) | March 2007 | May 2012 |
| NCT00456716 | Completed | Phase 2 | Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma | March 2007 | December 2008 |
| NCT00461851 | Completed | Phase 2 | Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma | March 2007 | August 2013 |
| NCT00464919 | Completed | Phase 2 | Sorafenib Plus Tegafur/Uracil (UFUR®) for Hepatocellular Carcinoma (HCC) | April 2007 | March 2009 |
| NCT00466232 | Completed | Phase 1 | Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer | April 2007 | March 2010 |
| NCT00467025 | Completed | Phase 2 | AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib | May 2007 | June 2014 |
| NCT00474786 | Completed | Phase 3 | Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib | September 2007 | January 2013 |
| NCT00474929 | Completed | Phase 1/Phase 2 | Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma | August 29, 2007 | August 8, 2019 |
| NCT00478114 | Completed | Phase 3 | Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC) | May 2007 | March 2010 |
| NCT00478374 | Completed | Phase 1 | Sorafenib With TACE to Treat Hepatocellular Carcinoma | May 2007 | January 2009 |
| NCT00480389 | Completed | Phase 2 | Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal | May 2007 | March 2013 |
| NCT00785226 | Completed | Phase 1/Phase 2 | RDEA119 and Sorafenib Combination Dose Escalation Study | November 2008 | April 2012 |
| NCT00789763 | Completed | Phase 1 | Phase I-II to Evaluate Efficacy/Safety of Sorafenib+Gemcitabine+Radiotherapy in Locally Advanced Pancreatic Carcinoma | December 2007 | January 2012 |
| NCT00810394 | Completed | Phase 2 | Sorafenib in Treating Patients With Advanced Malignant Solid Tumors | December 2008 | March 2012 |
| NCT00813293 | Completed | Phase 2 | Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer | June 2009 | November 2013 |
| NCT00815295 | Completed | Phase 1/Phase 2 | Study of Sorafenib/Cetuximab in Head and Neck Cancer | January 2008 | July 2013 |
| NCT00825734 | Completed | Phase 1/Phase 2 | Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer | March 2009 | August 2014 |
| NCT00837876 | Completed | Phase 2 | Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery | October 2008 | November 2012 |
| NCT00844883 | Completed | Phase 2 | Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma | February 2009 | March 2015 |
| NCT00846131 | Completed | Phase 1 | Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma | February 2009 | September 2016 |
| NCT00848640 | Completed | Phase 2 | Study of Sorafenib in Patients With Advanced Renal Cell Carcinoma | October 2008 | March 2010 |
| NCT00854620 | Completed | Phase 2 | Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer | December 2007 | January 2011 |
| NCT00858871 | Completed | Phase 3 | First Line Hepato Cellular Carcinoma (HCC) | May 2009 | September 2013 |
| NCT00861419 | Completed | Phase 1 | To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib. | December 2005 | |
| NCT00864032 | Completed | Phase 1/Phase 2 | Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body Wall | March 2009 | August 2011 |
| NCT00870532 | Completed | Phase 1 | Study of Combination of Metronomic Oral Vinorelbine and Sorafenib in Patients With Advanced Non-small Cell Lung Cancer | June 2008 | September 2013 |
| NCT00872014 | Completed | Phase 2 | A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer | August 2009 | June 2015 |
| NCT00875615 | Completed | Phase 2 | Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | December 2008 | June 2012 |
| NCT00882869 | Completed | Phase 1/Phase 2 | XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) | March 2009 | May 2011 |
| NCT00889057 | Completed | Phase 2 | Sorafenib in Relapsed High Grade Osteosarcoma | January 2008 | June 2011 |
| NCT00892424 | Completed | Phase 1/Phase 2 | Sorafenib-RT Treatment for Liver Metastasis (SLIM) | November 2008 | September 8, 2020 |
| NCT00892658 | Completed | Phase 1 | Sorafenib-RT in Treating Hepatocellular Carcinoma (SHEP) | January 2009 | December 16, 2020 |
| NCT00893373 | Completed | Phase 2 | Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years of Age | March 2009 | September 2014 |
| NCT00906373 | Completed | Phase 2 | A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver | May 2009 | May 2014 |
| NCT00908167 | Completed | Phase 1 | Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies | September 2009 | June 2015 |
| NCT00919061 | Completed | Phase 2 | Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy | August 2009 | March 2014 |
| NCT00920816 | Completed | Phase 3 | Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer | August 25, 2009 | April 29, 2021 |
| NCT00942682 | Completed | Phase 1 | Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors | July 2009 | March 2013 |
| NCT00943449 | Completed | Phase 2 | 4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma | July 2009 | September 2013 |
| NCT00943943 | Completed | Phase 1 | Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations | October 29, 2010 | March 23, 2017 |
| NCT00954278 | Completed | Phase 1 | Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer | July 28, 2009 | December 23, 2015 |
| NCT00956436 | Completed | Phase 1 | Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC) | August 2009 | April 2011 |
| NCT00976170 | Completed | Phase 1 | Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma) | September 2009 | September 2014 |
| NCT00987935 | Completed | Phase 2 | A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients | October 2009 | January 2016 |
| NCT00997022 | Completed | Phase 1 | Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients | May 2009 | May 2015 |
| NCT01004003 | Completed | Phase 2 | Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma | October 22, 2009 | October 12, 2016 |
| NCT01030783 | Completed | Phase 3 | A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma | December 2009 | June 2013 |
| NCT01033240 | Completed | Phase 2 | CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer | July 9, 2010 | September 9, 2013 |
| NCT01047891 | Completed | Phase 2 | Efficacy and Safety Study of Sorafenib With Topotecan in Patients With Platinum-resistant Recurrent Ovarian Cancer | January 2010 | February 2015 |
| NCT01076010 | Completed | Phase 3 | An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301). | March 2010 | July 2014 |
| NCT01078961 | Completed | Phase 1 | An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma | September 2010 | June 2016 |
| NCT01091207 | Completed | Phase 2 | Sorafenib for Imatinib/Sunitinib-failed GIST | November 2009 | August 2011 |
| NCT01128998 | Completed | Phase 1 | Sorafenib Plus S-1 in Advanced Solid Tumors | November 2009 | October 2015 |
| NCT01183663 | Completed | Phase 1 | Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) | August 2010 | May 2016 |
| NCT01189370 | Completed | Phase 2 | Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer | June 2008 | April 2015 |
| NCT01197170 | Completed | Phase 1 | Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance | September 7, 2010 | January 13, 2021 |
| NCT01223027 | Completed | Phase 3 | Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma | March 2011 | June 2014 |
| NCT01232296 | Completed | Phase 2 | A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment | July 2011 | April 2014 |
| NCT01246986 | Completed | Phase 2 | A Study of LY2157299 in Participants With Hepatocellular Carcinoma | March 30, 2011 | December 24, 2019 |
| NCT01248247 | Completed | Phase 2 | BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer | June 2, 2011 | November 30, 2020 |
| NCT01254890 | Completed | Phase 1/Phase 2 | Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome | January 2011 | March 2015 |
| NCT01258608 | Completed | Phase 1/Phase 2 | Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma | February 8, 2011 | November 29, 2017 |
| NCT01262482 | Completed | Phase 2 | Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment | October 2008 | December 2011 |
| NCT01271504 | Completed | Phase 1/Phase 2 | E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma | July 19, 2011 | June 23, 2015 |
| NCT01306058 | Completed | Phase 1/Phase 2 | Sorafenib and TRC105 in Hepatocellular Cancer | February 11, 2011 | June 9, 2017 |
| NCT01308723 | Completed | Phase 1 | A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma | March 2011 | January 2012 |
| NCT01357486 | Completed | Phase 2 | Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis | November 14, 2011 | April 12, 2017 |
| NCT01376453 | Completed | Phase 1 | Pre-operative 5-Fluorouracil (5-FU) and Sorafenib With External Radiation in Locally Advanced Rectal Cancer | June 2011 | March 2016 |
| NCT01398501 | Completed | Phase 1 | Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant | August 2011 | August 2016 |
| NCT01409499 | Completed | Phase 4 | Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC) | January 2011 | January 2018 |
| NCT01434602 | Completed | Phase 1/Phase 2 | Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas | October 2, 2012 | July 13, 2021 |
| NCT01482442 | Completed | Phase 3 | SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma | December 2011 | April 2016 |
| NCT01498952 | Completed | Phase 1 | MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC. | January 17, 2012 | April 9, 2013 |
| NCT01507064 | Completed | Phase 2 | Neoadjuvant Sorafenib Therapy Prior to Laser Ablation for Hepatocellular Carcinoma | January 2012 | September 2016 |
| NCT01518413 | Completed | Phase 1 | Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors | December 2011 | January 2015 |
| NCT01561833 | Completed | Phase 1 | A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients | October 2009 | June 2013 |
| NCT01578109 | Completed | Phase 1 | Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia | January 13, 2012 | March 7, 2021 |
| NCT01636908 | Completed | N/A | Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies. | August 2011 | December 1, 2019 |
| NCT01640665 | Completed | Phase 1 | Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors | July 2012 | August 2014 |
| NCT01683149 | Completed | Phase 1 | Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies | January 2013 | January 2016 |
| NCT01703455 | Completed | Phase 2 | Activity of Sorafenib in Salivary Gland Cancer | September 2010 | January 2013 |
| NCT01714609 | Completed | Phase 2 | The Effect of Sorafenib on Portal Pressure | August 2011 | September 2014 |
| NCT01724606 | Completed | Phase 1 | Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM) | November 5, 2012 | March 1, 2022 |
| NCT01754987 | Completed | Phase 1/Phase 2 | A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective | September 2012 | January 2016 |
| NCT01761266 | Completed | Phase 3 | A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma | March 1, 2013 | March 10, 2021 |
| NCT01762150 | Completed | Phase 2 | Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma | June 2011 | June 2018 |
| NCT01775501 | Completed | Phase 2 | Sorafenib + mFOLFOX for Hepatocellular Carcinoma | January 2013 | December 2019 |
| NCT01804374 | Completed | Phase 2 | Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma | June 2011 | December 2014 |
| NCT01844947 | Completed | Phase 1 | Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract | May 2012 | June 5, 2018 |
| NCT01893099 | Completed | Phase 1 | Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma | June 2013 | November 28, 2017 |
| NCT01897038 | Completed | Phase 1 | A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma | September 2013 | March 2015 |
| NCT01900002 | Completed | Phase 2 | Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | September 13, 2013 | December 10, 2020 |
| NCT01901692 | Completed | Phase 2/Phase 3 | Sorafenib vs.TransArterial Chemoembolization Plus RadioTherapy in Hepatocellular Carcinoma With Macrovascular Invasion | July 29, 2013 | August 31, 2017 |
| NCT01903694 | Completed | Phase 3 | Randomized Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular Carcinoma | March 2010 | |
| NCT01932385 | Completed | Phase 2/Phase 3 | Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma | August 1, 2013 | July 30, 2016 |
| NCT01988493 | Completed | Phase 1/Phase 2 | Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma | January 6, 2014 | December 3, 2020 |
| NCT02084732 | Completed | Phase 2 | Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study | October 1, 2013 | November 1, 2019 |
| NCT02135874 | Completed | Phase 2 | Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia | October 27, 2014 | February 21, 2023 |
| NCT02178358 | Completed | Phase 2 | A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma | August 8, 2014 | February 18, 2021 |
| NCT02196857 | Completed | Phase 2 | Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation | February 6, 2015 | November 27, 2018 |
| NCT02240433 | Completed | Phase 1 | A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC) | November 12, 2014 | December 25, 2019 |
| NCT02270788 | Completed | Phase 1 | Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies | April 2, 2015 | October 17, 2016 |
| NCT02279719 | Completed | Phase 1/Phase 2 | A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma | December 2014 | October 2019 |
| NCT02292173 | Completed | Phase 1 | Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer | February 18, 2015 | January 2021 |
| NCT02349867 | Completed | Phase 1 | Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer | January 29, 2015 | May 13, 2022 |
| NCT02354898 | Completed | Phase 1 | A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma | March 2015 | October 2018 |
| NCT02358395 | Completed | Phase 1 | A Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma | February 2015 | November 2017 |
| NCT02400788 | Completed | Phase 1/Phase 2 | Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC) | April 2013 | October 2016 |
| NCT02406521 | Completed | Phase 1 | Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets | April 2015 | December 31, 2019 |
| NCT02425605 | Completed | Phase 2 | Efficacy of Localized Concurrent Chemo-radiation Therapy and Sorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma | December 3, 2014 | September 22, 2017 |
| NCT02450149 | Completed | N/A | Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors | May 30, 2016 | August 9, 2016 |
| NCT02474290 | Completed | Phase 2/Phase 3 | Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML | June 20, 2015 | August 10, 2019 |
| NCT02530476 | Completed | Phase 1/Phase 2 | Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia | December 8, 2015 | April 8, 2019 |
| NCT02560779 | Completed | Phase 1/Phase 2 | Trial of TRC105 and Sorafenib in Patients With HCC | November 2016 | August 2019 |
| NCT02562755 | Completed | Phase 3 | Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone | October 2015 | July 2020 |
| NCT02576509 | Completed | Phase 3 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | December 7, 2015 | February 7, 2024 |
| NCT02599337 | Completed | Phase 1 | Bioequivalence Study of Sorafenib Tablet and Nexavar | July 2015 | October 2015 |
| NCT02627963 | Completed | Phase 3 | A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC) | May 24, 2016 | June 21, 2021 |
| NCT02636426 | Completed | Phase 1 | Sorafenib Administered Using a High-dose, Pulsatile Regimen: a Phase I Exposure Escalation Study | September 2015 | December 27, 2017 |
| NCT02645981 | Completed | Phase 2/Phase 3 | Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma | March 2016 | December 17, 2019 |
| NCT02716766 | Completed | Phase 2 | Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC) | March 2016 | September 2018 |
| NCT02728050 | Completed | Phase 1/Phase 2 | Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | December 1, 2016 | April 4, 2023 |
| NCT02774187 | Completed | Phase 3 | Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC | May 2016 | August 2018 |
| NCT02961998 | Completed | Phase 4 | Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single Center, Randomized Controlled Clinical Trail | July 2015 | July 2016 |
| NCT02971696 | Completed | Phase 3 | Sorafenib Versus Best Supportive Care in Egyptian Hepatocellular Carcinoma Patients. | December 2016 | January 2018 |
| NCT02973204 | Completed | Circulating Tumor Cells and Tumor DNA in HCC and NET | November 2016 | January 8, 2020 | |
| NCT02988440 | Completed | Phase 1 | Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients | April 20, 2017 | February 27, 2020 |
| NCT03009461 | Completed | Phase 2 | Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC With Major Portal Vein Tumor Thrombosis | June 1, 2017 | December 28, 2020 |
| NCT03170895 | Completed | Phase 2 | Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD | July 1, 2017 | March 1, 2020 |
| NCT03412773 | Completed | Phase 3 | Phase 3 Study of Tislelizumab Versus Sorafenib in Participants With Unresectable HCC | December 28, 2017 | December 14, 2023 |
| NCT03434379 | Completed | Phase 3 | A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma | March 15, 2018 | November 17, 2022 |
| NCT03578874 | Completed | Phase 2 | SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC | June 20, 2016 | April 30, 2019 |
| NCT03764293 | Completed | Phase 3 | A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC | June 10, 2019 | June 14, 2023 |
| NCT04553458 | Completed | Factors Affecting Post-treatment Outcomes in Patients With Hepatocellular Carcinoma | June 2015 | June 2020 | |
| NCT04788420 | Completed | Influence of Co-existing Mutations on Sorafenib Maintenance Therapy After Allo-HSCT for Patients With FLT3-ITD AML | January 1, 2012 | December 31, 2020 | |
| NCT05121571 | Completed | N/A | The Efficacy and Safety of HAIC With FOLFOX vs Sorafenib for Patients Who Showed TACE-resistant: a Retrospective Study | April 21, 2016 | May 1, 2021 |
| NCT05117957 | Enrolling by invitation | Phase 2 | Efficacy and Safety of Sorafenib in Previously Treated Advanced Hepatocellular Carcinoma: SOPT Study | February 8, 2022 | December 31, 2025 |
| NCT06177496 | Not yet recruiting | Influence of Sarcopenia in Hepatocellular Carcinoma Patients | February 1, 2024 | December 1, 2024 | |
| NCT06227221 | Not yet recruiting | Phase 2 | A Phase 2, Randomized, Placebo Controlled Study Investigating the Efficacy and Safety of Sorafenib in New-Onset Type 1 Diabetes Mellitus | June 2024 | December 2026 |
| NCT04992143 | Recruiting | Phase 2 | TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC | August 20, 2021 | December 30, 2023 |
| NCT04387695 | Recruiting | Phase 3 | SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT | April 30, 2020 | August 1, 2023 |
| NCT05596981 | Recruiting | The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or Without Sorafenib Maintenance After Allo-HSCT | October 1, 2022 | December 31, 2024 | |
| NCT06221683 | Recruiting | Phase 2 | Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML | March 2024 | December 2029 |
| NCT05713994 | Recruiting | Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma | May 19, 2020 | December 30, 2024 | |
| NCT05822752 | Recruiting | Phase 2 | Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) | September 21, 2023 | February 16, 2027 |
| NCT02559778 | Recruiting | Phase 2 | Pediatric Precision Laboratory Advanced Neuroblastoma Therapy | September 2015 | September 2035 |
| NCT03899428 | Recruiting | Phase 2 | Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC | May 2, 2019 | December 31, 2025 |
| NCT04720716 | Recruiting | Phase 3 | A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC | February 7, 2021 | December 1, 2023 |
| NCT04709380 | Recruiting | Phase 3 | Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT | March 2, 2021 | August 30, 2024 |
| NCT05596968 | Recruiting | The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD Positive AML After Allo-HSCT | October 1, 2022 | December 31, 2024 | |
| NCT05468359 | Recruiting | Phase 1/Phase 2 | Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients | November 7, 2022 | June 2037 |
| NCT05313958 | Recruiting | Phase 2/Phase 3 | Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children | December 1, 2021 | March 30, 2026 |
| NCT04135690 | Recruiting | Phase 2 | HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial | October 20, 2019 | December 20, 2023 |
| NCT02733809 | Recruiting | Phase 4 | Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma | January 2014 | December 2024 |
| NCT03132454 | Recruiting | Phase 1 | Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia | July 25, 2017 | December 31, 2024 |
| NCT05068752 | Recruiting | Phase 2 | Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer | October 28, 2021 | December 30, 2024 |
| NCT05717738 | Recruiting | Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma | January 20, 2022 | December 31, 2024 | |
| NCT05033522 | Recruiting | Phase 2/Phase 3 | Immunotherapy for Advanced Liver Cancer | August 1, 2023 | December 1, 2025 |
| NCT05601895 | Recruiting | The Gut Microbiome in FLT3- AL Undergoing Allo-HSCT With Or Without Sorafenib Maintenance | October 1, 2022 | December 31, 2024 | |
| NCT05669339 | Suspended | Phase 1 | AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma | June 2024 | April 2026 |
| NCT01887717 | Terminated | Phase 3 | Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein | February 27, 2014 | May 23, 2017 |
| NCT03878524 | Terminated | Phase 1 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | April 1, 2020 | December 10, 2020 |
| NCT00526799 | Terminated | Phase 1/Phase 2 | Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer | September 2007 | August 2010 |
| NCT02021929 | Terminated | Phase 2 | Sorafenib for Hepatopulmonary Syndrome | March 2014 | January 2018 |
| NCT04051853 | Terminated | Phase 2 | Sorafenib PK in Patients With Advanced HCC and Child-Pugh B | May 2014 | March 2017 |
| NCT02122003 | Terminated | Phase 2 | Second Line Sorafenib After Pazopanib in Patients With RCC | September 2016 | November 8, 2017 |
| NCT00632541 | Terminated | Phase 2 | A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer | October 2007 | March 2009 |
| NCT02220088 | Terminated | Phase 2/Phase 3 | The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial | December 2014 | July 2018 |
| NCT04326439 | Terminated | Phase 2 | AflacLL1901 (CHOA-AML) | January 24, 2020 | March 15, 2022 |
| NCT00779311 | Terminated | Phase 1 | A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer | October 2008 | March 2011 |
| NCT00791544 | Terminated | Phase 1/Phase 2 | Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma | November 2008 | November 2009 |
| NCT00619242 | Terminated | N/A | The Effects of Sorafenib on Molecular Barrett's Esophagus Cancer | June 2006 | September 2009 |
| NCT00811993 | Terminated | Phase 1 | A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors | February 2009 | December 2012 |
| NCT02323906 | Terminated | Phase 1 | Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer | January 16, 2015 | December 21, 2016 |
| NCT00525161 | Terminated | Phase 2 | Study Adding Multikinase Inhibitor Sorafenib to Existing Endocrine Therapy in Patients With Advanced Breast Cancer | October 2007 | January 2015 |
| NCT02412475 | Terminated | Phase 1 | Epigenetic Reprogramming in Relapse AML | February 21, 2015 | June 21, 2017 |
| NCT00510289 | Terminated | Phase 2 | Sorafenib in Myelodysplastic Syndrome | July 2006 | July 2011 |
| NCT00880542 | Terminated | Phase 2 | Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery | August 2008 | |
| NCT02460991 | Terminated | Phase 3 | A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma | November 2015 | June 5, 2017 |
| NCT00496756 | Terminated | Phase 2 | Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer | March 1, 2007 | April 25, 2014 |
| NCT00889343 | Terminated | Phase 2 | Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer | March 2009 | December 2012 |
| NCT00452387 | Terminated | Phase 2 | Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC) | May 2007 | January 2009 |
| NCT02560012 | Terminated | Phase 2 | Personalized Targeted Inhibitors Treatment in Renal Cell Cancer | January 4, 2016 | July 27, 2017 |
| NCT02575339 | Terminated | Phase 1/Phase 2 | MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma | July 18, 2016 | November 24, 2020 |
| NCT04985136 | Terminated | Phase 3 | A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC) | September 26, 2021 | December 29, 2021 |
| NCT00955721 | Terminated | Phase 1/Phase 2 | A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer | August 2009 | July 2014 |
| NCT00964743 | Terminated | N/A | Depocyt® With Sorafenib in Neoplastic Meningitis | August 2009 | February 2011 |
| NCT01005875 | Terminated | N/A | Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma | November 2009 | June 2013 |
| NCT01009593 | Terminated | Phase 3 | Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | January 2010 | July 2012 |
| NCT02748304 | Terminated | N/A | Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma | April 2016 | February 11, 2019 |
| NCT01141478 | Terminated | N/A | Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria | September 8, 2010 | June 10, 2016 |
| NCT01159327 | Terminated | Phase 2 | Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction Chemotherapy | December 2010 | June 2013 |
| NCT01171482 | Terminated | Phase 2 | Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma | November 2015 | April 2016 |
| NCT01194869 | Terminated | Phase 2 | Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer | June 2010 | June 2015 |
| NCT01215266 | Terminated | Phase 2 | Sorafenib in Urothelium Cancer of Bladder | October 2006 | June 2011 |
| NCT02867280 | Terminated | Phase 3 | Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection | June 1, 2016 | January 31, 2020 |
| NCT00618384 | Terminated | Phase 2 | TACE and Sorafenib for Advanced Hepatocellular Carcinoma (HCC) | January 2008 | August 2011 |
| NCT01342627 | Terminated | Phase 2 | Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma | October 2010 | September 2015 |
| NCT01348503 | Terminated | Phase 1 | Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma | May 2011 | March 2014 |
| NCT00595985 | Terminated | Phase 2 | Sorafenib as a Second Line Treatment in Patients With Advanced or Metastatic Gastric Cancer | July 2007 | January 2009 |
| NCT01405573 | Terminated | Phase 3 | Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma | July 2011 | March 2017 |
| NCT00589550 | Terminated | Phase 1 | PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer | February 2008 | January 2009 |
| NCT01425216 | Terminated | Phase 2 | Sorafenib for Patients With Extensive Keloids | March 2013 | March 2013 |
| NCT00576056 | Terminated | Phase 2 | Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC | January 2008 | April 2010 |
| NCT01480817 | Terminated | Phase 2 | Sorafenib VS TACE in HCC Patients With Portal Vein Invasion | June 2012 | December 2015 |
| NCT00543335 | Terminated | Phase 1 | Sorafenib and Thoracic Radiation for Patients With Non-Small Cell Lung Cancer | January 25, 2008 | January 2011 |
| NCT01510756 | Terminated | Phase 2 | Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL) | December 2011 | December 2014 |
| NCT01539018 | Terminated | Phase 2 | Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation and/or TACE | January 2012 | January 2015 |
| NCT01620216 | Terminated | Phase 2 | Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia | May 11, 2012 | April 30, 2017 |
| NCT00754923 | Terminated | Phase 2 | Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer | October 2008 | April 2012 |
| NCT03582618 | Terminated | Phase 2 | CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma | July 12, 2018 | December 30, 2022 |
| NCT03630120 | Terminated | Phase 2 | Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer | August 6, 2018 | December 5, 2019 |
| NCT00734526 | Terminated | Phase 1 | Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma | December 18, 2008 | December 2012 |
| NCT00532025 | Terminated | Phase 2 | Sorafenib in Resected Non-small Cell Lung Carcinoma | September 2007 | September 2008 |
| NCT00417248 | Terminated | Phase 1/Phase 2 | Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer | June 2007 | April 2008 |
| NCT00727532 | Terminated | N/A | Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer | July 2008 | September 2013 |
| NCT01849588 | Terminated | Phase 4 | HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC) | May 2013 | January 2017 |
| NCT00699374 | Terminated | Phase 3 | Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer | July 2008 | December 2011 |
| NCT03812770 | Unknown status | Phase 2 | Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC | August 4, 2018 | September 1, 2019 |
| NCT02311205 | Unknown status | Phase 2 | Efficacy and Safety of Concurrent TACE and Sorafenib in Patients With HCC and Extrahepatic Metastasis (COTSOM Study) | December 2014 | June 2018 |
| NCT03794440 | Unknown status | Phase 2/Phase 3 | A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma. | February 11, 2019 | December 2022 |
| NCT00794859 | Unknown status | Phase 2 | Sorafenib in Previously Treated Malignant Mesothelioma | October 2008 | |
| NCT04926532 | Unknown status | Phase 1/Phase 2 | Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular Carcinoma | August 1, 2019 | December 31, 2021 |
| NCT03730675 | Unknown status | N/A | Irradiation Stent Placement Plus TACE for HCC and PVTT | November 10, 2018 | November 10, 2021 |
| NCT03775395 | Unknown status | Phase 3 | HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC | December 12, 2018 | December 1, 2021 |
| NCT03606590 | Unknown status | Phase 2 | Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Sorafenib For Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA) | February 15, 2019 | September 2021 |
| NCT00786110 | Unknown status | Phase 2 | Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients | April 2008 | October 2010 |
| NCT01444807 | Unknown status | Phase 2 | Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases | December 2011 | March 2022 |
| NCT04163237 | Unknown status | Phase 3 | Combined Immunotherapy and Targeted Therapy for Advanced Liver Cancer | December 1, 2019 | November 30, 2020 |
| NCT02638428 | Unknown status | Phase 2 | Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy | December 2015 | December 2023 |
| NCT00999843 | Unknown status | Phase 1/Phase 2 | Safety Study of Sorafenib Following Combined Therapy of Radiation and TACE for Liver Cancer | October 2009 | October 2012 |
| NCT05113290 | Unknown status | Phase 4 | Effect and Safety of Recombinant Human Adenovirus Type 5 in Advanced HCC With Stable Disease After Sorafenib Treatment | December 28, 2021 | December 1, 2023 |
| NCT03812783 | Unknown status | Phase 2 | HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC | November 5, 2018 | December 1, 2019 |
| NCT02672488 | Unknown status | Phase 2 | Metformin Plus Sorafenib for Advanced HCC | December 2015 | December 2018 |
| NCT01041482 | Unknown status | Phase 2 | A Multi-Center, Non-Controlled Clinical Study of Sorafenib Adjuvant Therapy in Advanced Renal-Cell Carcinoma | November 2008 | November 2013 |
| NCT04152356 | Unknown status | Combined Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma | November 1, 2019 | September 1, 2020 | |
| NCT04143191 | Unknown status | Phase 3 | Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC | September 15, 2019 | September 15, 2023 |
| NCT03645980 | Unknown status | Phase 1/Phase 2 | DKN-01 Inhibition in Advanced Liver Cancer | October 10, 2018 | August 31, 2022 |
| NCT01170104 | Unknown status | Phase 2 | Trial of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib for Locally Advanced Hepatocellular Carcinoma (HCC) | June 2009 | June 2013 |
| NCT03468231 | Unknown status | Phase 3 | HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC | March 9, 2018 | March 9, 2020 |
| NCT00772694 | Unknown status | Phase 2 | Sorafenib Monotherapy in Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy | September 2008 | December 2011 |
| NCT02794337 | Unknown status | Phase 2/Phase 3 | TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer | December 2014 | January 2024 |
| NCT02836847 | Unknown status | Phase 2 | Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma | July 2016 | December 2020 |
| NCT01214343 | Unknown status | Phase 3 | Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC | October 2010 | September 2013 |
| NCT03518502 | Unknown status | Phase 4 | Sorafenib Monotherapy vs. TACE-sorafenib Sequential Therapy for HCC With Metastasis | March 1, 2012 | February 28, 2022 |
| NCT00541840 | Unknown status | Phase 1/Phase 2 | Phase I-II Trial of Sorafenib in Combination With Ifosfamide in Soft Tissue Sarcoma | October 2007 | April 2010 |
| NCT01230697 | Unknown status | Perspective Evaluation of Hormones Involved in Serum Phosphate Homeostasis in Patients With Metastatic Renal Cells Carcinoma or Hepatocellular Carcinoma Treated With Sorafenib (SORHORM) | June 2010 | September 2011 | |
| NCT05404516 | Unknown status | Phase 2 | Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML | January 1, 2020 | December 31, 2023 |
| NCT04127396 | Unknown status | Phase 4 | Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT | September 1, 2019 | December 1, 2021 |
| NCT02015728 | Unknown status | N/A | Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors | December 2013 | December 2017 |
| NCT01263951 | Unknown status | Phase 2 | Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone | November 2010 | May 2022 |
| NCT01265576 | Unknown status | Phase 2 | Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC) | December 2010 | April 2016 |
| NCT01272557 | Unknown status | Phase 2 | Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial | December 2010 | December 2014 |
| NCT00844688 | Unknown status | Phase 2 | Study of Sorafenib and Gemcitabine in Advanced Hepatocellular Carcinoma (HCC) | September 2008 | December 2009 |
| NCT00839111 | Unknown status | Phase 2 | Sorafenib and FOLFIRI Regimen in 2nd Colorectal Cancer (CRC) After Failure of Oxaliplatin Treatment | November 2008 | November 2010 |
| NCT04674345 | Unknown status | Phase 2/Phase 3 | Sorafenib Maintenance for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3 Negative Acute Leukemia | December 15, 2020 | December 31, 2023 |
| NCT03097848 | Unknown status | N/A | Efficacy and Safety of Sorafenib as Adjuvant and Latter Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma | May 4, 2017 | December 31, 2018 |
| NCT03971201 | Unknown status | Phase 2 | A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion | September 6, 2019 | June 30, 2023 |
| NCT02423239 | Unknown status | Phase 1 | A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours | April 2015 | December 2016 |
| NCT02330783 | Unknown status | Phase 2 | Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients | December 2014 | December 2018 |
| NCT02436902 | Unknown status | Phase 3 | Adjuvant Therapies for Patients With HCC and MVI | February 1, 2019 | August 30, 2022 |
| NCT01906216 | Unknown status | Phase 2/Phase 3 | Sorafenib Chemoembolization Evaluation Controlled Trial | September 2013 | December 2020 |
| NCT01377025 | Unknown status | Phase 2 | A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma | June 2011 | June 2017 |
| NCT02504983 | Unknown status | Phase 4 | Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular Carcinoma | August 2015 | July 2021 |
| NCT02529761 | Unknown status | N/A | TACE With or Without Sorafenib in Intermediate Stage Hepatocellular Carcinoma | August 2015 | October 2021 |
| NCT03178656 | Unknown status | Phase 4 | A Trial to Compare Surgery With Sorafenib for Hepatic Celluler Cancer With Portal Vein Tumor Thrombosis | December 15, 2016 | December 15, 2019 |
| NCT02537158 | Unknown status | N/A | Sorafenib and TACE as Adjuvant Therapy for MVI in HCC Patients After Radical Resection | August 2015 | July 2018 |
| NCT01801163 | Withdrawn | Phase 1 | A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC) | February 2012 | October 2014 |
| NCT02288507 | Withdrawn | Phase 1 | Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer | November 2014 | August 2016 |
| NCT03780634 | Withdrawn | Phase 2 | HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC | April 1, 2019 | December 1, 2021 |
| NCT00627835 | Withdrawn | Phase 1 | Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN) | ||
| NCT01608139 | Withdrawn | Phase 1 | Study of Curcumin, Vorinostat, and Sorafenib | November 2012 | |
| NCT01618253 | Withdrawn | Phase 1 | Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma | June 2012 | June 2016 |
| NCT01736878 | Withdrawn | Phase 2 | Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma | October 2012 | April 2013 |
| NCT03722498 | Withdrawn | Phase 2 | Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE | June 1, 2018 | March 22, 2021 |
| NCT03563170 | Withdrawn | Phase 1/Phase 2 | QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine | May 25, 2018 | August 23, 2019 |
| NCT02599090 | Withdrawn | Phase 2 | Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma | December 2008 | December 2012 |
| NCT04465734 | Withdrawn | Phase 3 | A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC | November 15, 2022 | March 15, 2024 |
| NCT02406508 | Withdrawn | Phase 2 | Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC | October 2014 | December 2017 |
| NCT02227914 | Withdrawn | Phase 1/Phase 2 | Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma | December 2014 | March 2015 |
| NCT01245582 | Withdrawn | Phase 3 | Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients | July 2011 | August 2015 |
| NCT02747537 | Withdrawn | Phase 2 | Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan | June 24, 2016 | February 29, 2020 |
| NCT02129322 | Withdrawn | Phase 2 | Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1 | July 2015 | December 2019 |
| NCT02691780 | Withdrawn | N/A | Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors | December 23, 2016 | November 19, 2019 |
| NCT02989870 | Withdrawn | Phase 1 | Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma | March 27, 2017 | October 15, 2018 |
| NCT00694291 | Withdrawn | Phase 2 | Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer | June 2008 |
- Trade name (Drug list of Screening Committee of Anticancer Drugs)
- Nexavar
- US Approved Year (20160209) (Drug list of Screening Committee of Anticancer Drugs)
- 2005
- Japan Approved Year (20160209) (Drug list of Screening Committee of Anticancer Drugs)
- 2008
- Target (Drug list of Screening Committee of Anticancer Drugs)
- Multi-kinases
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- 腎細胞がん
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- 肝細胞がん
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- 甲状腺がん